Thyrocare Technologies - Net loss of Rs. 18 Crore due to Covid-19 - Q4FY20

Thyrocare Technologies - Net loss of Rs. 18 Crore due to Covid-19 - Q4FY20


Thyrocare Technologies involves in provide Quality Diagnostic services in the Health care Segment in India. Established in the year 1996, the company conducts Clinical tests and laboratories. 


Currently, the Market capitalization for Thyrocare is Rs. 2800 Crore. Book value comes at Rs. 75 per Share. It is virtually a Debt Free Company, where the Debt to Equity stands at 0.03. The Promoters holding is said to be around 66 Percent and there is no pledging on Promoters Share holding.


The Interest coverage ratio (ICR) is also comes with sufficient numbers, around 120 Times. For the Last five years, the Sales growth is up 20 Percent and the Compounded profit growth were at 15 Percent. The Return on Equity (ROE) for the Thyrocare is 19 Percent over the past 5 years.


In Q4FY20 - quarterly results, the Company reported its revenue of Rs. 94 Crore. The Expenditure was Rs. 64 Crore in the said period. Rs. 44.33 Crore has been allocated in the Exceptional Items. It is said to be the provision for impairment of investments in Subsidiary.


As per the Financial report of Thyrocare, it is stated as below,



The Company assessed the recoverable amount of investment in the wholly owned subsidiary Nueclear Healthcare Limited, as at 31 March 2020, as the higher of Fair Value less Cost of Disposal (the 'FVCOD') and the Value in Use (the 'VIU'), in view of the accumulated business losses since inception and also considering the changes in the market conditions and business environment in India including due to the outbreak of COVID epidemic and effects thereof in the foreseeable future.


This has resulted in an impairment charge of INR 44.33 crore being recognised as exceptional charge for the quarter and year ended 31 March 2020. The Company continues to assess and endeavours to take appropriate steps to optimise the profitability of Nueclear Healthcare Limited and also combat the potential impacts of the COVID epidemic on the business of Nueclear Healthcare Limited.



Therefore, the company posted a net loss of Rs. 18 Crore in the Fourth quarter of FY2019-20. For the Financial year 2019-20, the standalone revenue from operations are Rs. 400 Crore and the Net profit was Rs. 79.44 Crore.


Earlier the revenue in the FY2018-19 was said to be Rs. 370 Crore and the Net profit was Rs. 95 Crore. The Cash Flow from operating activity seems  Positive. As per September 2019 quarter, the Reserves in Balance Sheet stood at Rs. 344 Crore.


Kindly share your views / comments with a smile :)


www.richinvestingideas.com


 





Comments

Post a Comment

Popular posts from this blog

What's your Earning - A Personal Cash Flow Meter

Image
What's your Earning  - A Personal Cash Flow Meter Earning money, isn't an easy one ? Absolutely, Earning money is an easy one, but it's hard to keep (grow) it. I mean that the Jobs and Earning money are easy on these techie days. Somebody have the value on their Dignity, Prosper and many of us have, earning more (Money) is a big value. Still, few one can make easy and more of them think that, it's hard to earn. Everyone of us, feeling that the rich one have more money and other's can't. But is it a right away to tell ? Not always, many of us hurting their health to make wealth (Money). Even Apple's Steve Jobs had earned a lot and respect too, but the health was not support for him. I am not telling you that, you have to earn more to be Rich (or) Financially Independent . The think is, how you utilize the earnings and to grow, while you have a little money or No job. What you have Earned ? As an individual, he earns  ₹  1,00,000 /- salary per month and spend
Read more

10 Years of TATA Motors Ltd - Financial Statement - Fundamental Insights

Image
10 Years of TATA Motors Ltd - Financial Statement - Fundamental Insights   Tata Motors Limited is a leading global automobile manufacturer and India's second largest company in Automotive segment next to Maruti Suzuki. It is the part of Tata Group, an Indian multi-national conglomerate which provides its products and services on Buses, Cars, Defense Vehicles, Sports utility vehicles, Trucks and other related automotive in it's segment. It is noteworthy that Tata Motors bought the famous and iconic brands Jaguar and Land Rover in the year 2008, from the Ford Company. Tata Motors is the leading player in the Commercial vehicle segment with a market share of around 45 Percent as per the FY2022. It is also said to be a Market leader in the EV segment with a market share of around 87 Percent in the year FY22 in India. The company's last dividend was declared in the year 2016 for the Financial year 2015-16 with an amount of Rs. 0.20 per Share. Tata Motors Ltd is trading in the In
Read more

Infosys Limited - FY2023 - Is it Undervalued or not ?

Image
Infosys Limited - FY2023 - Is it Undervalued or not ?   India's second largest IT(Information Technology) company were recently announced it's Q4FY23 and Financial year 2022-23 ending annual results. For the 2023 year ending results, it reported a sales of Rs. 1.46 Lakh crore and net profit of Rs. 24,108 crore. The sales increased by 21 percent and the net profit rose by 9 percent as compared to the FY2021-22. The company's revenue is primarily generated from the Digital business services, 63 percent of its total revenue. Digital services are such as AI based analytics, Big Data, IoT, Cloud applications, Advance cyber security systems, modernize legacy tech systems and Engineer digital products.  The revenue breakup is mostly coming from the Financial services segment with 32 percent of its total revenue, 15 percent in Retail segment, Telecom communication and media with 13 percent, Manufacturing with 11 percent and the rest of from other technology, Life sciences and Healt
Read more